US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
REGENXBIO Inc. - Common Stock
(NQ:
RGNX
)
7.430
+0.010 (+0.13%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about REGENXBIO Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
March 26, 2026
On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)...
Via
Finterra
Topics
Economy
Initial Public Offering
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
March 24, 2026
From
Pomerantz LLP
Via
GlobeNewswire
RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP
March 24, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
REGENXBIO INC (NASDAQ:RGNX) Stock Plunges 15% After Q4 Earnings Miss
↗
March 05, 2026
Via
Chartmill
RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
March 24, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
March 23, 2026
From
Schall Law
Via
GlobeNewswire
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
March 20, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm
March 19, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
REGENXBIO, Inc. Stockholders Should Contact Robbins LLP for Information About Leading the RGNX Class Action
March 19, 2026
From
Robbins LLP
Via
Business Wire
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
March 19, 2026
From
Schall Law
Via
GlobeNewswire
RGNX DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
March 19, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
March 17, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Stephen Pakola Oversaw RGX-111 Safety Claims That Cost RGNX Investors Millions: Levi & Korsinsky, LLP
March 17, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
ROSEN, LEADING TRIAL ATTORNEYS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
March 17, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
March 16, 2026
From
Schall Law
Via
GlobeNewswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
March 14, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
March 13, 2026
From
Schall Law
Via
GlobeNewswire
RGNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
March 12, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Regenxbio Says Its Gene Therapy For Muscle Disorder Showed No Evidence Of Liver Injury In Study
↗
March 11, 2026
The investigational gene therapy RGX-202 exhibited a favorable safety profile with no serious adverse events and no evidence of liver injury, the company said.
Via
Stocktwits
Topics
Death
RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP
March 10, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
March 10, 2026
From
Pomerantz LLP
Via
GlobeNewswire
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
March 10, 2026
From
Schall Law
Via
GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
March 08, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
March 06, 2026
From
Schall Law
Via
GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RGNX
March 05, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
REGENXBIO (RGNX) Q4 2025 Earnings Call Transcript
↗
March 05, 2026
REGENXBIO (RGNX) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
UPCOMING DEADLINE: REGENXBIO (RGNX) Securities Fraud Class Action – April 14, 2026 Lead Plaintiff Deadline
March 04, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
March 03, 2026
From
Pomerantz LLP
Via
GlobeNewswire
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
March 03, 2026
From
Schall Law
Via
GlobeNewswire
QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks?
↗
February 27, 2026
Analysts are divided on the target, with RBC Capital and Stifel saying the comments appeared to reference uniQure, while Leerink argued they more closely align with Regenxbio’s RGX-121.
Via
Stocktwits
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
